Sign in
Taking people in FrancePhase 4

Testing daridorexant for sleep problems in people with memory decline or mild Alzheimer disease

Tests daridorexant for insomnia in adults with mild memory decline or mild Alzheimer disease.

Key facts

Who runs it
Centre Hospitalier Universitaire De Montpellier
Where
Montpellier Cedex 5, FranceSee the site
Registry title
Daridorexant to treat insomnia in patients with mild cognitive impairment and mild to moderate Alzheimer disease.
Status
Recruiting
Phase
Phase 4
People taking part
62 people, planned
Started
14 Dec 2023
Expected to end
13 Mar 2028
Type of study
Interventional
Record updated
19 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for outpatients aged 60 to 85 with early Alzheimer disease or mild cognitive impairment who also have insomnia. It tests daridorexant 50 mg for sleep time.

Age
60 to 85 years
Sex
All sexes can join.
Disease stage
Mild cognitive impairment or early, mild-to-moderate Alzheimer disease, with MMSE 12 to 26 and CDR 0.5 to 2. Insomnia with total sleep time under 6 hours, at least 3 nights a week.
Earlier treatment
Anticholinesterase drugs, memantine, some antidepressants, neuroleptics and level 2 pain drugs are allowed if the dose was stable for at least 3 months. Hypnotics and level 3 pain drugs are not allowed.
Biomarker or test result
Positive CSF Aβ42 and/or positive plasma biomarker, and hippocampal and/or temporal atrophy on MRI. Baseline sleep study (PSG) must show total sleep time under 6 hours and wake after sleep onset over 1 hour.

Main reasons for not taking part

  • Patients who depend heavily on caregivers
  • Current psychiatric disorder (DSM-5)
  • Moderate or severe liver failure
  • Severe sleep-related breathing disorder (over 30 apnea/hypopnea episodes per hour)
  • History of narcolepsy or cataplexy, or of drug or alcohol abuse

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Age [60-85] years old
  • Outpatients
  • Pre-screening: • Complaints of dissatisfaction with sleep quantity or quality, despite adequate opportunity for sleep, at least 3 nights per week and for at least 3 months, and • Total sleep time causes clinically significant distress or impairment in daytime functioning, and • Total sleep time estimated by interview was below 6 hours, on at least 3 nights per week and for at least 1 month before screening
  • Baseline PSG (at randomization) assessed TST < 6 hours and WASO > 1 hour
  • Diagnosis of MCI and AD patients at an early stage according to the NIA diagnosis criteria (core clinical criteria for MCI, positive CSF Aβ42 and/or positive plasma biomarker, and neuronal injury (hippocampal and/or temporal atrophy by MRI))
  • MMSE from 12 to 26
  • Clinical Dementia Rating CDR from 0.5 to 2
  • Use of CNS-active medications is permitted provided the dose has been stable for at least 3 months, including: anticholinesterase drugs (rivastigmine, donepezil, galantamine) or memantine, antidepressants SSRI (e.g. fluoxetine, sertraline, paroxetine…), SNRI (e.g. venlafaxine, duloxetine), neuroleptics (e.g. clozapine, olanzapine, aripiprazole...) or drug for pain level 2 (codeine, tramadol)

Who cannot take part

  • Use of hypnotics (benzodiazepines, zolpidem, zopiclone) or drug for pain level 3 (morphine and derivatives)
  • Forbidden and restricted concomitant medications: • Concomitant CNS-depressant medicinal products • CYP3A4 inhibitors • CYP3A4 inducers
  • Participation in another clinical trial or administration of an investigational product
  • History of diagnosed and characterized psychiatric disorders (DSM-5), cured or stabilized (with or without the same treatment for at least 3 months) and excluding any current characterized psychiatric disorder (DSM-5), the diagnosis of which is established by a psychiatrist trained in geriatric psychiatry
  • Moderate and severe liver failure
  • PSG baseline evidence of significant/severe sleep-related breathing disorder (defined as >30 apnea/hypopnea episodes per hour)
  • Hypersensitivity to the active substance or to any of the excipients listed in the Summary of Product Characteristics (SmPC)
  • Failure to obtain written informed consent after a reflection period
  • History of narcolepsy and/or cataplexy
  • History of drug or alcohol abuse or addiction
  • Patients significantly dependent on caregivers
  • Treatments interfering with sleep-wake patterns
  • Protected population according to articles of the French Public Health Code (e.g. patients under law protection, prisoners, pregnant, parturient or lactating women, and patients under guardianship/curatorship)
  • Subjects not covered by public health insurance
  • Institutionalized patients
  • Analphabetism or subjects unable to read or/and write
  • Patients unable to perform the neuropsychological tests
  • Patients unable to complete the study instruments (sleep diary)
  • Planned longer stay outside the region that prevents compliance with the visit schedule
  • Patients who cannot be followed up for at least 2 months

Where in France

  • University Hospital Of MontpellierMontpellier Cedex 5, FranceTaking people

About the trial

What the trial wants to find out

To evaluate the efficacy of oral administration of daridorexant 50 mg on the total sleep time (TST) duration as assessed via polysomnography from baseline to post-baseline, in outpatients with MCI and mild-to-moderate AD, with insomnia disorder.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Daridorexant to treat insomnia in patients with mild cognitive impairment and mild to moderate Alzheimer disease.
Plain-language title
Testing daridorexant for sleep problems in people with memory decline or mild Alzheimer diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
19 June 2026